Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

MolDX lists three named assays for recurrence testing in advanced colorectal cancer

The MolDX billing article A58434, in the revision effective January 1, 2026, lists Signatera, Guardant Reveal, and Oncodetect for the diagnosis of progression, recurrence, or relapse in advanced colorectal cancer.

CMS MolDX